Prognostic value of tgfb1 protein in endometrioid adenocarcinoma

European Journal of Clinical Investigation

Volumn 43, Issue 1, 2013, Pages 79-90

  Soufla, Giannoula ^a   Sifakis, Stavros ^b   Porichis, Filippos ^a   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Endometrial cancer; mRNA expression; Protein; RT PCR; TGFB1; Vascular endothelial growth factor

Indexed keywords

BETA ACTIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOWN REGULATION; ENDOMETRIOID ADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CELL TRANSFORMATION, NEOPLASTIC; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84871618867     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12017     Document Type: Article

References (34)

1. Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 1995;86:479-85.
2. Seki N, Kodama J, Hongo A, Miyagi Y, Yoshinouchi M, Kudo T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer. Eur J Cancer 2000;36:68-73.
3. Salvensen HB, Akslen LA. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 1999;84:538-43.
4. Soufla G, Porichis F, Sourvinos G, Vassilaros S, Spandidos DA. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis. Cancer Lett 2006;235:100-13.
5. Das K, Zhao Y, Sugiomoto M, Lau W, Tan PH, Cheng C. Differential expression of vascular endothelial growth factor 165b in transitional cell carcinoma of the bladder. Urol Oncol 2007;25:317-21.
6. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T et al. Prognostic significance of vegf expression in human ovarian carcinoma. Br J Cancer 2000;83:196-203.
7. Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF, Brown LF. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1996;78:454-60.
8. Yokoyama Y, Sato S, Futagami M, Fukushi Y, Sakamoto T, Umemoto M et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol Oncol 2000;77:413-8.
9. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 2001;80:181-8.
10. Sivridis E, Giatromanolaki A, Anastasiadis P, Georgiou L, Gatter KC, Harris AL et al. Tumour and angiogenesis research group angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. J Pathol 2002;196:416-22.
11. Chen CA, Cheng WF, Lee CN, Wei LH, Chu JS, Hsieh FJ et al. Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival. Gynecol Oncol 2001;80:207-12.
12. Fine BA, Valente PT, Feinstein GI, Dey T. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol 2000;76:33-9.
13. Talvensaari-Mattila A, Soini Y, Santala M. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol 2005;26:81-7.
14. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-91.
15. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR et al. GF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003;12:1116-24.
16. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
17. Hazelbag S, Gorter A, Kenter GG, Van den Broek L, Fleuren G. Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol 2002;33:1193-9.
18. Parekh TV, Gama P, Wen X, Demopoulos R, Munger JS, Carcangiu ML et al. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. Cancer Res 2002;62:2778-90.
19. Lecanda J, Parekh T, Gama P, Lin K, Liarski V, Uretsky S et al. Transforming growth factor-β, estrogen and progesterone converge on the regulation of p27kip1 in the normal and malignant endometrium. Cancer Res 2007;67:1007-18.
20. Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T. Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. Cancer Lett 1998;134:15-22.
21. Holland CM, Day K, Evans A, Smith SK. Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 2003;89:891-8.
22. O'Toole SA, Dunn E, Sheppard BL, Sheils O, O'Leary JJ, Wuttke W et al. Oestrogen regulated gene expression in normal and malignant endometrial tissue. Maturitas 2005;51:187-98.
23. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004;17:197-203.
24. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007;13:7487-95.
25. Wilson TO, Podratz KC, Gaffey TA, Malkasian GD, O'Brien PC, Naessens JM. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 1990;162:418-23.
26. Fanning J, Evans MC, Peters AJ, Samuel M, Harmon ER, Bates JS. Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile. Gynecol Oncol 1989;32:288.
27. Sanseverino F, Santopietro R, Torricelli M, D'Andrilli G, Russo G, Cevenini G et al. pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biol Ther 2006;5:84-8.
28. Strick R, Ackermann S, Langbein M, Swiatek J, Schubert SW, Hashemolhosseini S et al. Proliferation and cell-cell fusion of endometrial carcinoma are induced by the human endogenous retroviral Syncytin-1 and regulated by TGF-beta. J Mol Med 2007;85:23-38.
29. Perlino E, Loverro G, Maiorano E, Giannini T, Cazzolla A, Napoli A et al. Down-regulated expression of transforming growth factor beta 1 mRNA in endometrial carcinoma. Br J Cancer 1998;77:1260-6.
30. Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E, Spandidos DA. VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett 2005;221:105-18.
31. Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006;29:305-14.
32. Muinelo-Romay L, Colas E, Barbazan J, Alonso-Alconada L, Alonso-Nocelo M, Bouso M et al. High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion. Mol Cancer Ther 2011;10:1357-66.
33. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmond HP, Bouchier-Hayes DJ. TGF beta-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol 1997;4:621-7.
34. Mhawech-Fauceglia P, Kesterson J, Wang D, Akers S, Dupont NC, Clark K et al. Expression and clinical significance of the transforming growth factor-β signalling pathway in endometrial cancer. Histopathology 2011;59:63-72.